


**Supplementary Fig. S1.** Representative images of the aortic wall in remission patients with severe AR caused by BS. **A)** Low power shows lymphocytes focally aggregate in the severely fibrous adventitia (HE); **B)** High power shows mild degeneration in the fibrous intima (HE); **C-F)** High power shows a few lymphocytes scattered in the adventitia; **C)** HE; **D)** CD4+; **E)** CD8+ and **F)** CD20+, at the corresponding location in the serial sections.



**Supplementary Fig. S2.** Representative images of the aortic valve in remission patients with severe AR caused by BS. **A)** Low power shows mild mucoid degeneration (HE); **B)** Fibrous with mild-to-moderate mucoid degeneration (HE); **C-F)** Lymphocytes imperceptibly scattered in the mild mucoid degeneration background; **C)** HE; **D)** CD4+; **E)** CD8+ and **F)** CD20+ at the corresponding location in the serial sections.

## Clinicopathology of severe aortic valve regurgitation caused by BS / M. Zhang et al.

Supplementary Table S1. Pathological parameter of the aortic valve in patients with severe AR caused by BS.

| Pathological parameter of aortic valve |                                      |                 | Active BS  | Remission BS |  |
|--|--------------------------------------|-----------------|------------|--------------|--|
| Inflammatory cell infiltration         |                                      |                 | 5/5 (100%) | 13/13 (100%) |  |
| HE assessment                          | Cell type                            | Neutrophils     | 3/5 (60%)* | 1/13 (7.7%)* |  |
|  | •                                    | Eosinophils     | 1/5 (20%)  | 1/13 (7.7%)  |  |
|  |                                      | Lymphocytes     | 5/5 (100%) | 13/13 (100%) |  |
|  |                                      | Plasma cells    | 0/5 (0%)   | 2/13 (15.4%) |  |
|  | Distribution                         | Diffuse         | 4/5 (80%)  | 4/13 (30.8%) |  |
|  |                                      | Scattered/Focal | 1/5 (20%)  | 9/13 (69.2%) |  |
| IHC assessment                         | CD4 <sup>+</sup> T cell infiltration |                 | 5/5 (100%) | 5/5 (100%)   |  |
|  | Distribution                         | Diffuse         | 3/5 (60%)  | 1/5 (20%)    |  |
|  |                                      | Scattered/Focal | 2/5 (40%)  | 4/5 (80%)    |  |
|  | CD8+ T cell infiltration             |                 | 4/5 (80%)  | 4/5 (80%)    |  |
|  | Distribution                         | Diffuse         | 3/4 (75%)  | 1/4 (25%)    |  |
|  |                                      | Scattered/Focal | 1/4 (25%)  | 3/4 (75%)    |  |
|  | CD20+ B cell infiltration            |                 | 4/5 (80%)  | 2/5 (40%)    |  |
|  | Distribution                         | Diffuse         | 0/4 (0%)   | 0/2 (0%)     |  |
|  |                                      | Scattered/Focal | 4/4 (100%) | 2/2 (100%)   |  |
|  | CD68+ macrophage infiltration        |                 | 4/5 (80%)  | 3/5 (60%)    |  |
|  | Distribution                         | Diffuse         | 3/4 (75%)  | 0/3 (0%)     |  |
|  |                                      | Scattered/Focal | 1/4 (25%)  | 3/3 (100%)   |  |
| Mucoid degeneration                    |                                      |                 | 2/5 (40%)  | 8/13 (61.5%) |  |
| Neovascularisation                     |                                      |                 | 4/5 (80%)  | 7/13 (53.9%) |  |
| Fibrous tissue proliferation           |                                      |                 | 5/5 (100%) | 13/13 (100%) |  |
| Calcification                          |                                      |                 | 1/5 (20%)  | 2/13 (15.4%) |  |
| Necrosis                               |                                      |                 | 4/5 (80%)  | 6/13 (46.2%) |  |

HE: haematoxylin and eosin; IHC: immunohistochemistry. \*indicates a statistically significant difference between active BS and remission BS, with p<0.05.

## Supplementary Table S2. Pathological parameter of the aortic wall in BS patients with or without preoperatively biologics.

| Pathological parameter of aortic wall |                | Intima            |                       | Media                               |                       | Adventitia                          |                                 |                                     |
|---------------------------------------|----------------|-------------------|-----------------------|-------------------------------------|-----------------------|-------------------------------------|---------------------------------|-------------------------------------|
|                                       |                |                   | GCs ±<br>Immunosuppr. | GCs+<br>Immunosuppr.<br>+ Biologics | GCs ±<br>Immunosuppr. | GCs+<br>Immunosuppr.<br>+ Biologics | GCs ±<br>Immunosuppr.<br>ressan | GCs+<br>Immunosuppr.<br>+ Biologics |
| Inflammatory cell infiltration        |                |                   | 12/14 (85.7%)         | 5/5 (100%)                          | 14/14 ( 100%)         | 5/5 (100%)                          | 13/14 (92.9%)                   | 5/5 (100%)                          |
| HE assessment                         | Cell type      | Neutrophils       | 0/12 (0%)             | 0/5 (0%)                            | 1/14 (7.1%)           | 0/5 (0%)                            | 8/13 (61.6%)                    | 1/5 (20%)                           |
|                                       |                | Eosinophils       | 0/12 (0%)             | 0/5 (0%)                            | 0/14 (0%)             | 0/5 (0%)                            | 9/13 (69.2%)                    | 2/5 (40%)                           |
|                                       |                | Lymphocytes       | 12/12 (100%)          | 5/5 (100%)                          | 14/14 (100%)          | 5/5 (100%)                          | 13/13 (100%)                    | 5/5 (100%)                          |
|                                       |                | Plasma cells      | 0/12 (0%)             | 0/5 (0%)                            | 0/14 (0%)             | 0/5 (0%)                            | 13/13 (100%)                    | 5/5 (100%)                          |
|                                       | Distribution   | Diffuse           | 3/12 (25%)            | 0/5 (0%)                            | 1/14 (7.1%)           | 0/5 (0%)                            | 4/13 (30.8%)                    | 0/5 (0%)                            |
|                                       |                | Scattered/Focal   | 9/12 (75%)            | 5/5 (100%)                          | 13/14 (92.9%)         | 5/5 (100%)                          | 9/13 (69.2%)                    | 5/5 (100%)                          |
| IHC assessment                        | CD4+ T cell in | nfiltration       | 8/14 (57.2%)          | 2/5 (40%)                           | 6/14 (42.9%)          | 1/5 (20%)                           | 14/14 (100%)                    | 5/5 (100%)                          |
|                                       | Distribution   | Diffuse           | 2/8 (25%)             | 1/2 (50%)                           | 2/6 (33.3%)           | 0/1 (0%)                            | 8/14 (57.1%)*                   | 0/5 (0%)*                           |
|                                       |                | Scattered/Focal   | 6/8 (75%)             | 1/2 (50%)                           | 4/6 (66.7%)           | 1/1 (100%)                          | 6/14 (42.9%)                    | 5/5 (100%)                          |
|                                       | CD8+ T cell in | nfiltration       | 12/14 (85.7%)         | 4/5 (80%)                           | 10/14 (71.4%)         | 3/5 (60%)                           | 12/14 (85.7%)                   | 5/5 (100%)                          |
|                                       | Distribution   | Diffuse           | 1/12 (8.3%)           | 1/4 (25%)                           | 1/10 (10%)            | 0/5 (0%)                            | 6/12 (50%)                      | 1/5 (20%)                           |
|                                       |                | Scattered/Focal   | 11/12 (91.7%)         | 3/4 (75%)                           | 9/10 (90%)            | 3/3 (100%)                          | 6/12 (50%)                      | 4/5 (80%)                           |
| D                                     | CD20+ B cell   | infiltration      | 1/14 (7.1%)           | 0/5 (0%)                            | 3/14 (21.4%)          | 0/5 (0%)                            | 12/14 (85.7%)                   | 4/5 (80%)                           |
|                                       | Distribution   | Diffuse           | 0/1 (0%)              | / 0/3 (0%)                          | /                     | 0/12 (0%)                           | 0/4 (0%)                        |                                     |
|                                       |                | Scattered/Focal   | 1/1 (100%)            | / 3/3 (1009                         | 6) /                  | 12/12 (100%)                        | 4/4 (100%)                      |                                     |
|                                       | CD68+ macro    | phage infiltratio | n 5/14 (35.7%)        | 2/5 (40%)                           | 4/14 (28.6%)          | 1/5 (20%)                           | 8/14 (57.2%)*                   | 0/5 (0%)*                           |
|                                       | Distribution   | Diffuse           | 0/5 (0%)              | 0/2 (0%)                            | 0/4 (0%)              | 0/1 (0%)                            | 2/8 (25%)                       | /                                   |
|                                       |                | Scattered/Focal   | 5/5 (100%)            | 2/2 (100%)                          | 4/4 (100%)            | 1/1 (100%)                          | 6/8 (75%)                       | /                                   |
| Mucoid degenerat                      | ion            |                   | 9/14 (64.3%)          | 5/5 (100%)                          | 7/14 (50%)            | 4/5 (80%)                           | 1/14 (7.1%)                     | 1/5 (20%)                           |
| Fibrous tissue proliferation          |                | 12/14 (85.7%)     | 5/5 (100%)            | 14/14 (100%)                        | 5/5 (100%)            | 12/14 (85.7%)                       | 5/5 (100%)                      |                                     |
| Vasa vasorum mu                       |                | on                | 1                     | 1                                   | / ` '                 | 1                                   | 12/14 (85.7%)*                  |                                     |
| Neurofibril thicker                   |                |                   | /                     | /                                   | /                     | /                                   | 10/14 (71.4%)                   | 1/5 (20%)                           |
| Granulation tissue                    |                |                   | /                     | /                                   | /                     | /                                   | 6/14 (42.9%)                    | 0/5 (0%)                            |

HE: haematoxylin and eosin; IHC: immunohistochemistry; /: not applicable. \*indicates a statistically significant difference between active BS and remission BS, with p < 0.05.

## Clinicopathology of severe aortic valve regurgitation caused by BS / M. Zhang et al.

Supplementary Table S3. Pathological parameter of the aortic valve in BS patients with or without preoperatively biologics.

| Pathological parameter of ac   | ortic valve                               |                 |       | Cs ±<br>suppressant | immunos | Cs +<br>suppressant<br>ologics |
|--------------------------------|---|-----------------|-------|---------------------|---------|--------------------------------|
| Inflammatory cell infiltration | n   |                 | 14/14 | (100%)              | 4/4     | (100%)                         |
| HE assessment                  | Cell type                                 | Neutrophils     | 4/14  | (28.6%)             | 0/4     | (0%)                           |
|                                |   | Eosinophils     | 2/14  | (14.3%)             | 0/4     | (0%)                           |
|                                |   | Lymphocytes     | 14/14 | (100%)              | 4/4     | (100%)                         |
|                                |   | Plasma cells    | 2/14  | (14.3%)             | 0/4     | (0%)                           |
|                                | Distribution                              | Diffuse         | 7/14  | (50%)               | 1/4     | (25%)                          |
|                                |   | Scattered/Focal | 7/14  | (50%)               | 3/4     | (75%)                          |
| IHC assessment                 | CD4+ T cell infiltration                  |                 | 8/8   | (100%)              | 2/2     | (100%)                         |
|                                | Distribution                              | Diffuse         | 4/8   | (50%)               | 0/2     | (0%)                           |
|                                |   | Scattered/Focal | 4/8   | (50%)               | 2/2     | (100%)                         |
|                                | CD8+ T cell infiltration                  |                 | 7/8   | (87.5%)             | 1/2     | (50%)                          |
|                                | Distribution                              | Diffuse         | 4/7   | (57.1%)             | 0/1     | (0%)                           |
|                                |   | Scattered/Focal | 3/7   | (42.9%)             | 1/1     | (100%)                         |
|                                | CD20 <sup>+</sup> B cell infiltration     |                 | 6/8   | (75%)               | 0/4     | (0%)                           |
|                                | Distribution                              | Diffuse         | 0/6   | (0%)                | /       |                                |
|                                |   | Scattered/Focal | 6/6   | (100%)              | /       |                                |
|                                | CD68 <sup>+</sup> macrophage infiltration |                 | 6/8   | (75%)               | 1/2     | (50%)                          |
|                                | Distribution                              | Diffuse         | 3/6   | (50%)               | 0/1     | (0%)                           |
|                                |   | Scattered/Focal | 3/6   | (50%)               | 1/1     | (100%)                         |
| Mucoid degeneration            |   |                 | 6/14  | (42.9%)             | 4/4     | (100%)                         |
| Fibrous tissue proliferation   |   |                 | 14/14 | (100%)              | 4/4     | (100%)                         |
| Calcification                  |   |                 | 3/14  | (21.4%)             | 0/4     | (0%)                           |
| Necrosis                       |   |                 | 10/14 | (71.4%)*            | 0/4     | (0%)*                          |

HE: haematoxylin and eosin; IHC: immunohistochemistry; /: not applicable. \*indicates a statistically significant difference between active BS and remission BS, with p < 0.05.